Longevity Research Library · Educational Use Only

SS-31 (Elamipretide) Mitochondrial Research: Mechanism, Aging & Data

Last reviewed 2026 · Source: peer-reviewed preclinical literature

What is SS-31?

SS-31, also known as Elamipretide (MTP-131), is a tetrapeptide with the sequence D-Arg-dimethylTyr-Lys-Phe-NH2. It was developed by Hazel Szeto and Peter Schiller at Weill Cornell Medical College and is one of the most rigorously studied mitochondria-targeted peptides in aging and cardiometabolic research.

Mechanism: Cardiolipin Binding

SS-31's primary mechanism involves binding to cardiolipin — a unique phospholipid found almost exclusively in the inner mitochondrial membrane (IMM). Cardiolipin anchors key IMM proteins including cytochrome c, Complex I, and ATP synthase. In aging and disease, cardiolipin undergoes peroxidation and structural changes that impair electron transport chain (ETC) efficiency.

SS-31 binds to cardiolipin, stabilising its interaction with ETC proteins and reducing cardiolipin peroxidation. This directly improves electron flow through the ETC, reduces proton leak, increases membrane potential, and restores ATP production efficiency.

Age-Related Mitochondrial Decline

Aging is consistently associated with reduced mitochondrial membrane potential, increased reactive oxygen species (ROS) production, and impaired ATP synthesis — collectively termed "mitochondrial dysfunction." SS-31 research has demonstrated that these age-related impairments are not irreversible: studies in aged rodents showed that 8 weeks of SS-31 administration substantially restored mitochondrial function to levels approaching young controls.

Cardiac Research

The largest clinical research programme for SS-31 involves ischemia-reperfusion injury and heart failure. BSCR (STARBRITE) Phase 2 trials showed reductions in myocardial damage markers post-PCI. MMPOWER-3 (Phase 3 in heart failure) enrolled patients with HFpEF (heart failure with preserved ejection fraction) — a condition with few effective treatments and strong mitochondrial dysfunction involvement.

Skeletal Muscle Research

Preclinical data shows SS-31 reverses age-related skeletal muscle mitochondrial dysfunction, improving exercise capacity and reducing fatigue in aged rodent models. Clinical Phase 2 data (SPIMM-201) showed improved 6-minute walk distance in patients with mitochondrial myopathy after 4 weeks of treatment.

Research Dosing

SS-31 in clinical trials has been administered intravenously or subcutaneously at 0.05–0.25 mg/kg. For research purposes, subcutaneous administration at 1–5 mg doses is most common. QSC supplies SS-31 in 5 mg vials.

Research-grade peptides with HPLC-verified COA
All compounds referenced in this guide are available at QSC Peptides (qscpeptide.com) — US domestic warehouse, fast shipping, batch-level certificates of analysis.

This page is for educational and research purposes only. All products sold by QSC are labelled for research use only and are not intended for human consumption. Nothing on this page constitutes medical advice.